132 related articles for article (PubMed ID: 38458271)
1. The Safety and Efficacy of a "No Touch" Abortion Program Implemented in the Greater Toronto Area During the COVID-19 Pandemic.
Smith MK; Biderman M; Frotten E; Warden S; Dunn S; Dmytryshyn R; Thorne JG
J Obstet Gynaecol Can; 2024 Jun; 46(6):102429. PubMed ID: 38458271
[TBL] [Abstract][Full Text] [Related]
2. Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.
Raymond EG; Grossman D; Mark A; Upadhyay UD; Dean G; Creinin MD; Coplon L; Perritt J; Atrio JM; Taylor D; Gold M
Contraception; 2020 Jun; 101(6):361-366. PubMed ID: 32305289
[No Abstract] [Full Text] [Related]
3. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.
Chong E; Shochet T; Raymond E; Platais I; Anger HA; Raidoo S; Soon R; Grant MS; Haskell S; Tocce K; Baldwin MK; Boraas CM; Bednarek PH; Banks J; Coplon L; Thompson F; Priegue E; Winikoff B
Contraception; 2021 Jul; 104(1):43-48. PubMed ID: 33781762
[TBL] [Abstract][Full Text] [Related]
4. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.
Goldstone P; Michelson J; Williamson E
Med J Aust; 2012 Sep; 197(5):282-6. PubMed ID: 22938126
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
Gatter M; Cleland K; Nucatola DL
Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
[TBL] [Abstract][Full Text] [Related]
6. Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation.
Boydell N; Reynolds-Wright JJ; Cameron ST; Harden J
BJOG; 2021 Oct; 128(11):1752-1761. PubMed ID: 34138505
[TBL] [Abstract][Full Text] [Related]
7. Outcomes During Early Implementation of Mifepristone-Buccal Misoprostol Abortions up to 63 Days of Gestation in a Canadian Clinical Setting.
Warden S; Genkin I; Hum S; Dunn S
J Obstet Gynaecol Can; 2019 May; 41(5):647-652. PubMed ID: 31007171
[TBL] [Abstract][Full Text] [Related]
8. Misoprostol in the era of COVID-19: a love letter to the original medical abortion pill.
Jayaweera RT; Moseson H; Gerdts C
Sex Reprod Health Matters; 2020 Dec; 28(1):1829406. PubMed ID: 33111643
[No Abstract] [Full Text] [Related]
9. Current and potential methods for second trimester abortion.
Lerma K; Blumenthal PD
Best Pract Res Clin Obstet Gynaecol; 2020 Feb; 63():24-36. PubMed ID: 31281014
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of a hospital outpatient day procedure for medication abortion at 13-18 weeks gestation: Findings from Nepal
Blum J; Karki C; Tamang A; Shochet T; Shrestha A; Tuladhar H; Karki A; Sharma J; Abbas DF; Dragoman M; Winikoff B
Contraception; 2019 Dec; 100(6):451-456. PubMed ID: 31491379
[TBL] [Abstract][Full Text] [Related]
11. Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.
Kerestes C; Murayama S; Tyson J; Natavio M; Seamon E; Raidoo S; Lacar L; Bowen E; Soon R; Platais I; Kaneshiro B; Stowers P
Contraception; 2021 Jul; 104(1):49-53. PubMed ID: 33789080
[TBL] [Abstract][Full Text] [Related]
12. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
Abubeker FA; Lavelanet A; Rodriguez MI; Kim C
BMC Womens Health; 2020 Jul; 20(1):142. PubMed ID: 32635921
[TBL] [Abstract][Full Text] [Related]
13. Early pregnancy termination with mifepristone and misoprostol in Norway.
Bjørge L; Johnsen SL; Midbøe G; Augestad G; Økland I; Helland H; Stray-Pedersen S; Iversen OE
Acta Obstet Gynecol Scand; 2001 Nov; 80(11):1056-61. PubMed ID: 11703208
[TBL] [Abstract][Full Text] [Related]
14. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation.
Hsia JK; Lohr PA; Taylor J; Creinin MD
Contraception; 2019 Sep; 100(3):178-181. PubMed ID: 31102629
[TBL] [Abstract][Full Text] [Related]
15. Simplified medical abortion screening: a demonstration project.
Raymond EG; Tan YL; Comendant R; Sagaidac I; Hodorogea S; Grant M; Sanhueza P; Van Pratt E; Gillespie G; Boraas C; Weaver MA; Platais I; Bousieguez M; Winikoff B
Contraception; 2018 Apr; 97(4):292-296. PubMed ID: 29170088
[TBL] [Abstract][Full Text] [Related]
16. Medical management of early pregnancy loss with mifepristone and misoprostol in emergency departments compared to a Complex Family Planning office: Implementation of a COVID-19 institutional policy change.
Bleck RR; Danvers AA; Nimbvikar A; Gurney EP
Contraception; 2024 Aug; 136():110467. PubMed ID: 38641155
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial.
Elami-Suzin M; Freeman MD; Porat N; Rojansky N; Laufer N; Ben-Meir A
Obstet Gynecol; 2013 Oct; 122(4):815-820. PubMed ID: 24084539
[TBL] [Abstract][Full Text] [Related]
18. A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14-21 weeks of pregnancy.
Dabash R; Chelli H; Hajri S; Shochet T; Raghavan S; Winikoff B
Int J Gynaecol Obstet; 2015 Jul; 130(1):40-4. PubMed ID: 25896965
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of low-dose misoprostol in the induced labor of 16 to 28 weeks pathological pregnancies (a STROBE-compliant article).
Yang Y; Wang Y; Du X; Duan J; Huang YM
Medicine (Baltimore); 2019 Oct; 98(40):e17396. PubMed ID: 31577749
[TBL] [Abstract][Full Text] [Related]
20. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.
Ashok PW; Flett GM; Templeton A
Lancet; 1998 Aug; 352(9127):542-3. PubMed ID: 9716062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
